Shah Gaurav reported option exercise involving 76,490 derivative units of ROCKET PHARMACEUTICALS, INC. at $1.69 for −$129k on May 21, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CEO
CEO
Filed May 26, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
−$129,344.59Shares × reported price
Shares traded
76,490Stock Option (Right to Buy)
Price per share
$1.69Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
May 21, 2026Option exercise
Filed
May 26, 2026, 7:47 PM ET5-day reporting delay
Accession
0001140361-26-022894Code M · Transaction 385326
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 21, 2026Option exercise76,490$1.69$129,344.59Trade 385324
May 21, 2026Sell55,684$3.09−$171,840.82Trade 385325
3 transaction rows in this filing. Joint filers share the same rows.

RCKT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RCKT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +22%1w ago +13%1d ago −1%
Returns since7d −3.7%30d +8%90d +18%180d1y

Footnotes in full

F1: Holdings include Restricted Stock Units that convert to common stock on a one-for-one basis. F2: Represents shares received upon exercise of a Stock Option in advance of the expiration of such Stock Option. F3: Represents shares sold by the Reporting Person in order to pay the exercise price of a Stock Option and to cover certain taxes in connection with the exercise of the Stock Option. F4: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.105. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5: This option represents a right to purchase a total of 76,490 shares of the Issuer's Common Stock, one-third of which became fully vested and exercisable on April 12, 2018, with the remaining two-thirds vesting in equal quarterly installments over the following two years.